RxDoctor Payments Data

Kinji Hawthorne, MD

Internal Medicine · la Quinta, CANPI 1023208683

Payments from drug & device makers

$3,242in general payments, 2019–2025

Across 123 payments — averaging $26.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$590
  • La Jolla Pharmaceutical Company$447
  • Merck$364
  • Johnson & Johnson$339
  • Paratek Pharmaceuticals, Inc.$269
  • Viiv Healthcare Company$246
  • plus $986 from 13 others

What the payments were for

  • Food & beverage$3,11296%
  • Education$1304%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,242 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$1,294
Medicare patients
11
Services billed
11

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TriumeqAbacavir/Dolutegravir/Lamivudi21$82,742
Daptomycin42$27,047
CeftriaxoneCeftriaxone Sodium49$4,096
Tigecycline13$3,874
Fosfomycin Tromethamine17$3,701
Methenamine Hippurate38$3,296
Doxycycline Hyclate27$1,504
Fluconazole11$748
Amoxicillin18$427
Azithromycin15$372
Clindamycin Hcl22$354
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim20$181
Mupirocin11$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq$246$82,74221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in la Quinta

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →